drugset / Trial / NCT04928612
A Study of CBP-1018 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, non-randomized, multi-center, phase I study of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors. This study will be conducted in 2 parts: Part A (Dose Escalation) and Part B (Dose Expansion). Both parts include screening period, treatment period, end of treatment (EOT)/withdrawal, safety follow-up (SFU) and long-term-follow-up (LTFU). CBP-1018 will be administrated on eligible subjects until disease progression, unacceptable toxicity, withdrawal of consent or Sponsor's decision to stop the study, etc.
Timeline
- Start
- 2021-11-04
- Primary completion
- 2024-10
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBP-1018 | Other / unclassified | 0.03 mg/kg | Intravenous |
| Subject | CBP-1018 | Other / unclassified | 0.06 mg/kg | Intravenous |
| Subject | CBP-1018 | Other / unclassified | 0.08 mg/kg | Intravenous |
| Subject | CBP-1018 | Other / unclassified | 0.1 mg/kg | Intravenous |
| Subject | CBP-1018 | Other / unclassified | 0.12 mg/kg | Intravenous |
| Subject | CBP-1018 | Other / unclassified | 0.14 mg/kg | Intravenous |